CHILDREN'S DIMETAPP COLD & ALLERGY OTC
Generic Name and Formulations:
Brompheniramine maleate 1mg, phenylephrine HCl 2.5mg; per 5mL; syrup; alcohol-free; grape-flavor; contains sodium 3mg/5mL.
Pfizer Consumer Healthcare
Indications for CHILDREN'S DIMETAPP COLD & ALLERGY:
Rhinorrhea, allergy symptoms, nasal congestion.
20mL every 4 hours; max 6 doses/24 hours.
<6yrs: do not use. 6–11yrs: 10mL every 4 hours; max 6 doses/24 hours.
Children <6yrs old. During or within 14 days of MAOIs. For use as a sedative hypnotic.
Hypertension. Cardiovascular disease. Thyroid disease. Diabetes. Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants. Avoid alcohol.
Antihistamine + sympathomimetic.
Drowsiness, anticholinergic effects, dizziness, nervousness, insomnia, excitability in children.
Syrup—4oz, 8oz (w. dosing cup)
Clinical Pain Advisor Articles
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Chronic Pain Associated With Traumatic Brain Injury: Causes and Management
- Perturbation-Based Rehabilitation Effective for Chronic Low Back Pain
- Migraine Frequency Correlated With Depression and Anxiety
- IBS-Associated Chronic Pain: Formulation of Core Diagnostic Criteria
- Cannabis Use Associated With Aberrant Drug Behaviors
- Walgreens to Carry Naloxone in All Pharmacies to Combat Drug Abuse
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Pain Processing: Examining the Role of Oxytocin
- Short- vs Long-Acting Opioids for Osteoarthritis Pain
- Extended-Release Naltrexone Injections Reduce Opioid Dependence
- Depressive Symptoms Among Medical Interns Increased With Work-Family Conflicts
- CMS Launches Initiative to Analyze Regulation Impact on Patient Care